8 results about "Therapy efficacy" patented technology

A system and method for distinguishing non-failing from failing cardiac fibroblasts (CFs) using advanced imaging techniques and machine learning (ML). The method involves staining CFs with fluorescent dyes to highlight key cellular components, such as nuclei and actin fibers. Images are analyzed to extract morphological features, which are then processed and normalized. A supervised ML system, trained on labeled CF data, classifies CFs based on phenotypic differences. The system enables accurate diagnosis of heart failure (HF), facilitates screening for therapeutic efficacy, and identifies antifibrotic agents by evaluating changes in CF phenotypes pre- and post-treatment.

DEPCT64 This invention relates to 4 / 91IBV (Infectious Bronchitis Virus) which is coded for... Heterologous S (spike) protein or fragments thereof; furthermore, this invention also... This is related to the components that elicit an immune response, which include the aforementioned 4 / 91IBV. Process the code for heterologous S (spike) protein or fragments thereof. This invention also relates to a method for immunizing targets, which includes: Providing the target with an element that induces an immune response to this invention. Furthermore, this invention relates to methods for treating or preventing clinical symptoms caused by IBV. The necessary objectives involve a method of providing the target with the required quantity. The therapeutic efficacy of the immune response-inducing components according to this invention. -----------------------------------------------------------

This invention relates to an instrument for treating neurological or psychiatric disorders using i-wave periodicity-dependent four-pulse theta burst stimulation (iQPS). The system includes a transcranial magnetic stimulation (TMS) stimulator configured to deliver test pulses to a target motor cortex region and therapeutic theta bursts to a treatment region, wherein the pulse frequency is customized according to the patient's individual i-wave periodicity. An electromyography (EMG) device records motor evoked potentials (MEPs) from the target muscles and analyzes the intervals between MEPs to determine the i-wave periodicity. Personalized stimulation enhances cortical plasticity by synchronizing stimulation with the brain's intrinsic neural timing. This invention is applicable to neurological and psychiatric conditions including depression, schizophrenia, stroke recovery, and neuropathic pain. Advantages include improved therapeutic efficacy, reduced patient response variability, and a non-invasive adaptive therapy model aligned with the patient's unique neurophysiological characteristics, thus providing a precise and scalable approach to brain stimulation.

A cyclocurcumin-based composition comprising: cyclocurcumin in an amount of 25 to 40% by weight of the total composition; one or more residual curcuminoids, including curcumin and demethoxycurcumin, in a total amount of 8 to 18% by weight; an antioxidant stabilizer selected from ascorbic acid, tocopherol, or a combination thereof in an amount of 3 to 8% by weight; a bioavailability enhancer containing piperine in an amount of 1 to 3% by weight; and a pharmaceutically acceptable excipient in an amount of 40 to 60% by weight.

Methods and systems for treating sleep disordered breathing and assessing and improving efficacy of treatment of sleep disordered breathing re disclosed herein. According to some embodiments, the present technology includes a method of treating sleep disordered breathing with a neuromodulation system at least partially implanted in a patient having an airway compromised by an obstruction. The method includes delivering stimulation energy to a target nerve in the patient using an electrode of the neuromodulation system, wherein the target nerve is associated with patency of the airway, receiving sensor data from a sensor arrangement of the neuromodulation system, wherein the sensor data is indicative of airflow in the airway proximal to the obstruction, and assessing efficacy of the stimulation energy based at least in part on the received sensor data.

The present application relates to a kind of pharmaceutical composition for enhancing the efficacy of CAR-T cell, the pharmaceutical composition includes therapeutically effective amount of lysosomal inhibitor and pharmaceutically acceptable carrier.The present application first proposes and verifies by adjusting the endocytosis post-transport pathway of tumor cell itself, can overcome its CD4 + Resistance of CAR-T cell therapy provides new strategies for solving the heterogeneity of CAR-T therapy efficacy;The lysosomal inhibitor used is a drug that has been clinically used, and its safety is relatively clear, and CD4 + The clinical transformation potential of CAR-T cell combination therapy is large, and can be quickly applied to existing CAR-T treatment plan.

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory diseases using the pharmaceutical composition disclosed herein.

DEPCT64 This invention relates to H52IBV (infectious bronchitis virus) with the encoding for... Heterologous S (spike) protein or fragments thereof; furthermore, this invention also... This is related to the components that elicit an immune response, which include the aforementioned H52IBV. Process the code for heterologous S (spike) protein or fragments thereof. This invention also relates to a method for immunizing targets, which includes: Providing the target with an element that induces an immune response to this invention. Furthermore, this invention relates to methods for treating or preventing clinical symptoms caused by IBV. The necessary objectives involve a method of providing the target with the required quantity. The therapeutic efficacy of the immune response-inducing components according to this invention. -----------------------------------------------------------